RO7123520
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for RO7123520, covering 2020-01-29 to 2020-01-29. Get the full timeline:
Most recent: Clinical Trial Update: A Study of RO7123520 to Evaluate the Safety and Efficacy in Participants With Moderately To Severely Active Rheumatoid Arthritis (RA) Who Are Inadequately Responding to Anti-Tumor Necrosis Factor (TNF)-Alpha Therapy [Phase 2]